Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Anti Cancer Drugs. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN105646414A details an eco-friendly three-step synthesis. This method offers significant cost reduction and supply chain reliability for high-purity pharmaceutical intermediates.
Patent CN111087338B reveals a copper-catalyzed route for sulfonamide-substituted pyrrolidones, offering cost reduction and scalable manufacturing for pharmaceutical intermediates.
Patent CN103012239B enables one-pot synthesis for anticancer intermediates. Delivers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN117820316B enables high-purity chiral API intermediates through mild catalytic synthesis with industrial scalability and significant cost-saving potential.
Solve chiral drug synthesis challenges with metal-free catalysis. Achieve >99% ee, mild conditions, and scalable production for pharmaceutical intermediates. Reduce costs and supply chain risks.
Discover high-yield phosphabenzopyran synthesis for Hep G2 cytotoxicity. Our CDMO expertise enables scalable production with 95%+ yields and cost savings.
Skip Boc protection steps and cut 15% production costs with this 5-step Taladegib route. Our CDMO expertise ensures >99% purity and scalable manufacturing.
Solve chiral purity challenges in halichondrin synthesis with 99.7% ee and 92% yield. Reduce impurity removal burden for Eribulin mesylate production. CDMO expertise for scalable manufacturing.
Solve chiral purity challenges in halichondrin synthesis. Our CDMO expertise delivers >99% ee intermediates with 92% yield, reducing impurity risks for oncology drug development.
Discover how advanced cuprous bromide activation and palladium-catalyzed hydrogenation reduce solid waste by 90% while achieving 99.8% purity and 72% yield for AZD9291 production.
Solve supply chain risks and low yields in anticancer intermediate production. Discover a 4-step, 84% yield route using common raw materials. Contact us for scalable CDMO solutions.
Solve 2,3-dihydroquinolone synthesis challenges with high-yield palladium-catalyzed carbonylation. Reduce costs and scale up for anti-cancer drug development.
Discover how metal-free photoredox catalysis enables high-yield, enantioselective synthesis of chiral thiochroman-4-ketones for anticancer drug development. Reduce supply chain risks and GMP compliance costs.
Discover how metal-free photoredox catalysis enables high-yield, enantioselective synthesis of chiral chroman-4-ones for anticancer drug development. Reduce supply chain risks and improve purity.
Solve low enantioselectivity & high cost in chiral indole synthesis. This patent's mild, scalable method delivers >90% ee & 98% yield for anti-tumor drug intermediates. Request COA now.
Discover high-yield, cost-effective synthesis of pyrrole derivative anti-tumor compounds. Our CDMO expertise ensures 90%+ yields and 6.5μg/mL IC50 for Hep G2. Scale up with us.
Discover a novel chiral synthesis method for isopyrone-indole derivatives with 92% ee and 80% yield. Ideal for oncology drug development.
Discover a scalable, high-yield route for 3-arylquinoline-2(1H) ketone derivatives using benzisoxazole as dual source. Reduce production costs and supply chain risks with this efficient CDMO solution.
Solve low yield and safety issues in chiral indole synthesis. Our CDMO expertise delivers 90-95% ee and 64-98% yield for anti-tumor drug intermediates.
Discover efficient, scalable synthesis of N-N axis chiral bisindoles with >93% ee and 87% yield. Ideal for pharmaceutical R&D and procurement to accelerate prostate cancer drug development.